Effects of Sarcopenia and Sarcopenic Obesity in Complex Abdominal Wall Surgery

December 26, 2020 updated by: Luis Blázquez Hernando, Hospital Universitario Ramon y Cajal

Sarcopenia and Sarcopenic Obesity in Complex Abdominal Wall Surgery: Postoperative Complications and Their Impact on Recurrence

The objective of our study is to evaluate the prevalence of sarcopenia and sarcopenic obesity in our surgical population and their relationship in postoperative complications after complex abdominal wall surgery and its influence on hernia recurrence.

This is a retrospective study on a prospective maintains database of complex abdominal wall surgery.

We select patients with defects larger than 10 cm from any location (W3 of the EHS classification), excluding other causes of complex abdominal wall in order to have a more homogeneous sample.

Pre-surgical computed tomography (CT) scans of the selected patients will be reviewed to establish the diagnosis of sarcopenia, obesity, sarcopenia-obesity or the absence of these (normal). The CT scans will be reviewed by two trained investigators, blinded to postoperative complications and survival. In case of disagreement, a third investigator will break the tie.

The radiological diagnosis of sarcopenia has been established based on the skeletal muscle mass index. Skeletal muscle mass measurement will be performed in a cross-section in the pre-surgical CT scan at the level of the third lumbar vertebra (L3).

The BMI, the Visceral Fat Area and the Subcutaneous Fat Area (SFA) will also be measured. With the previous data, the VFA / SFA ratio will be calculated.

The study will be completed with the collection of sociodemographic data, comorbidities and presence of risk factors for the development of incisional hernia, ASA, size and location of the hernia, surgical technique, postoperative complications according to Clavien-Dindo, stay, readmission, late complications and hernia recurrence. Likewise, the presence or absence of recurrence will be collected.

Statistical analysis will be performed to see if there is a correlation between sarcopenia and sarcopenic obesity with the appearance of local and systemic complications and recurrence. To evaluate the independent contribution of each variable to the presence of complications, a univariate and multivariate logistic regression analysis will be performed.

Study Overview

Status

Unknown

Conditions

Detailed Description

The incidence of incisional hernia after laparotomy is as high as 20% according to current literature, and repair of incisional hernias is one of the most frequently performed operations by general surgeons. A not inconsiderable part of these hernias, due to their size, complexity or degree of contamination, is considered complex abdominal wall. Surgery in these patients is a major surgery that is accompanied by a marked anabolic response and a high incidence of local and systemic complications and a high recurrence rate.

In recent years, there has been a growing interest in evaluating the relationship between surgical results and body composition. Sarcopenia is a new concept that reflects the loss of skeletal muscle mass. Recent publications have recognized sarcopenia as a prognostic factor in the evolution of surgical patients operated on for cancer, transplants, trauma and emergency surgery, but there is still little evidence that it plays a role in surgery for the complex abdominal wall.

The prevalence of sarcopenia is growing progressively. One of the causes may be that life expectancy has increased worldwide and is well known that ageing is associated with the progressive loss of muscle mass (9).

Sarcopenia can be classified into primary, which is caused by ageing, and secondary, which is caused by immobility or diseases such as cancer (10).

On the other hand, obesity is defined as abnormal or excessive accumulation of fat mass. It is a major public health problem and is recognized as a risk factor for global morbidity and mortality. Its incidence continues to increase worldwide and its prevalence has doubled since 1980 (11). It is well documented that visceral obesity is associated with high complication rates in patients who undergo abdominal wall surgery (12-15).

The body mass index (BMI) has long been used to diagnose malnutrition. However, weight gain and loss are not reliable indicators of changes in body composition; generally, men store body fat in the visceral area while women store it mainly subcutaneously. Also, people tend to lose muscle mass and gain fat as they age. Therefore, patients with a similar BMI may have a different nutritional status (16).

Sarcopenic obesity combines the risks of obesity and sarcopenia and is considered the worst-case scenario (17,18).

Objectives:

The objective of our study is to evaluate the prevalence of sarcopenia and sarcopenic obesity in our population. The aim is to evaluate its relationship in postoperative complications after complex abdominal wall surgery and its influence on hernia recurrence.

Material and methods:

A retrospective study on a prospective maintains database of complex abdominal wall surgery of three hospitals.

We have decided to select only patients with defects larger than 10 cm from any location (W3 of the EHS classification) (19), excluding other causes of complex abdominal wall in order to have a more homogeneous sample (2).

Study design:

In conjunction with the Radiology Department of Ramón y Cajal University Hospital, pre-surgical computed tomography (CT) scans will be reviewed to establish the diagnosis of sarcopenia, obesity, sarcopenia-obesity or the absence of these (normal). The CT scans will be reviewed by two trained investigators, blinded to postoperative complications and survival. In case of disagreement, a third investigator will break the tie.

The radiological diagnosis of sarcopenia has been established based on the skeletal muscle mass index. Skeletal muscle mass measurement will be performed in a cross-section in the pre-surgical CT scan at the level of the third lumbar vertebra (L3). To identify muscle tissue the range -29 to +150 in Hounsfield Units (HU) will be used. The L3 region contains the following muscles: psoas, paraspinal muscles, and muscles of the abdominal wall (transverse abdominis, external and internal obliques, rectus abdominis). The skeletal muscle mass index will be calculated with the sum of the cross-sectional areas of these muscles (cm2). These values will be normalized according to the square of the patient's height (m2). As a cut-off point for the diagnosis of sarcopenia, we will use the values published by Prado et al. (≤52.4 cm2 / m2 in men and ≤38.5 cm2 / m2 for women).

To define obesity we use several indexes. The most widely accepted is body mass index (BMI)> 30 kg / m2 (25-30 kg / m2-overweight). However, this index does not take into account muscle mass and fat distribution, which are associated with different risk profiles. The Visceral Fat Area (VFA) measured by CT is strongly correlated with BMI and waist circumference. Cross-sectional measurement of VFA demonstrates a stronger correlation than anthropomorphic measurements with obesity-related conditions, such as hypertriglyceridaemia, hypertension, hyperglycemia, and low levels of high-density lipoprotein (HDL) cholesterol. The VFA measurement will be performed in a cross-section in the preoperative CT scan at the L3 level. To identify fat tissue, the range -190 to -30 in Hounsfield Units (HU) will be used.

According to the Japanese Obesity Society, we will consider visceral obesity calculated by CT as a visceral fat area (VFA)> 100cm2, regardless of sex and age. Despite the fact that the Asian population and the Western population present important differences, this data has already been used previously in European series. To complete the study, the Subcutaneous Fat Area (SFA) will also be measured. With the previous data, the VFA / SFA ratio will be calculated. The patient will be considered viscerally obese when the VFA / SFA ratio is <0.4. This correction will be used to mitigate biases derived from using values in different populations.

The study will be completed with the collection of sociodemographic data, characteristics of the surgical procedure, as well as complications derived from it. Likewise, the presence or absence of recurrence will be collected.

Study variables: sex, age, comorbidities and presence of risk factors for the development of incisional hernia, ASA, weight, height, BMI, date of surgical intervention, size and location of the hernia, surgical technique, postoperative complications according to Clavien-Dindo , stay, readmission, late complications, hernia recurrence, end-date of follow-up. To evaluate patient-reported outcomes, a quality-of-life assessment was measured preoperatively and at 1- and 2-year follow-up, using the European Registry for Abdominal Wall Hernias Quality of Life (EuraHS-QoL) score, a hernia-specific tool developed by the European Hernia Society (20). In addition, the following will be collected by radiology: skeletal muscle mass index (Skeletal Muscle Index: SMI), visceral fat area (VFA) and subcutaneous fat area (SFA).

Procedures for collecting clinical data:

First, patients potentially candidates for the study will be selected from the complex abdominal wall database of the three participating hospitals.

Data of selected patients from Hospital Ramón y Cajal will be sent to the Radiology Department of the Ramón y Cajal University Hospital for the collection of SMI, VFA and SFA in the pre-surgical CT scan.

The preoperative CT scans of the selected patients from the Henares University Hospital and the Puerta de Hierro-Majadahonda University Hospital will be recorded on a computer device to be analyzed in the Radiology Department of the Ramón y Cajal University Hospital. Once the study variables have been calculated, computing devices containing preoperative CTs will be eliminated.

Statistical analysis:

The normality of the quantitative variables will be analyzed with the Kolmogorov-Smirnov test. Continuous variables will be expressed as mean with standard deviation, and categorical variables will be represented as proportions. For comparison analysis between groups, continuous variables will be compared using the Student's t-test and categorical variables will be analyzed, as appropriate, using the χ2 test or Fisher's exact test (univariate analysis).

For the analysis of hernia recurrence, the Kaplan-Meier method will be used. In the comparison of hernia recurrence between the groups, the long-rank test will be performed. In the multivariate analysis for hernia recurrence, the Cox regression model will be used, which will include the significant variables in the univariate analysis.

To evaluate the independent contribution of each variable to the presence of complications, a univariate and multivariate logistic regression analysis will be performed with the inclusion of candidate predictors, which are significant with p <0.200 in the univariate comparison analysis.

A statistically significant result will be considered when a value of p <0.05. SPSS Statistics Version 23 will be used for statistical analysis.

Study limitations:

Retrospective study.

Schedule of activities The approval of the Clinical Research Ethics Committee of the Ramón y Cajal University Hospital is expected to be obtained in January 2021.

After this, the patients candidates to participate in the study will be selected from the complex abdominal wall data base of the three participating hospitals. We estimate that this selection will be made in the month of February.

Once the patients have been selected, the parameters described in the materials and methods section will be determined in the preoperative CT scan of each patient. We estimate that the time required to complete this part of the study will be six to eight months.

Next, a statistical analysis will be made of the data obtained from the preoperative CT scan and from the complex abdominal wall surgery database and the results will be interpreted. A manuscript will be prepared to communicate the results obtained. We estimate that this process will be performed in two or three months.

Study benefits

  • To know the incidence of sarcopenia and sarcopenic obesity in complex abdominal wall patients.
  • To confirm whether sarcopenia and sarcopenic obesity are risk factors for the appearance of complications and recurrence after complex abdominal wall surgery.
  • This could help to better estimate the surgical risk of patients undergoing complex abdominal wall surgery.
  • Sarcopenia and sarcopenic obesity are potentially modifiable with a proper nutritional and physical exercise program. If we show that sarcopenia and sarcopenic obesity are risk factors for the appearance of complications, it could help to reduce the morbidity of these patients.

Study Type

Observational

Enrollment (Anticipated)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients undergoing complex abdominal wall surgery at the Ramón y Cajal University Hospital, at the Puerta de Hierro-Majadahona University Hospital and at the Henares University Hospital

Description

Inclusion Criteria:

  • Patients operated for an incisional hernia with a transverse diameter greater than 10 cm measured in the preoperative Computed Tomography.

Exclusion Criteria:

  • Not having a preoperative Computed Tomography performed in the three months before the operation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Complications
Time Frame: Thirty postoperative day
Presence of local or systemic complications
Thirty postoperative day
Recurrence
Time Frame: Twenty four postoperative month
Appearance of an incisional hernia recurrence
Twenty four postoperative month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospital Universitario Ramon y Cajal

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

January 18, 2021

Primary Completion (Anticipated)

August 15, 2021

Study Completion (Anticipated)

October 15, 2021

Study Registration Dates

First Submitted

December 26, 2020

First Submitted That Met QC Criteria

December 26, 2020

First Posted (Actual)

December 30, 2020

Study Record Updates

Last Update Posted (Actual)

December 30, 2020

Last Update Submitted That Met QC Criteria

December 26, 2020

Last Verified

December 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sarcopenia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe